EUVIMEDEUVIMED entdecken
Vergleichsstudie

Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma

Hyung-Don Kim, Young-Gyu Park, Hyeyeon Hong, Sung Won Chung, Sejin Kim, Min-Hee Ryu, Baek-Yeol Ryoo, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim und 3 weitere

Oncology · 21.03.2025 · 104 (1) · 40-50

DOI: 10.1159/000545351 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Oncology, online erschienen am 21.03.2025. Verfasst von Hyung-Don Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to compare the effectiveness outcomes of Child-Pugh class A patients with unresectable hepatocellular carcinoma (HCC) treated with first-line atezolizumab-bevacizumab and lenvatinib.

Methods

This retrospective study included patients with Child-Pugh A unresectable HCC who were administered first-line treatment with either atezolizumab-bevacizumab (n = 368) or lenvatinib (n = 229) at Asan Medical Center (Seoul, Korea). Effectiveness outcomes were analyzed along with the inverse probability treatment weighting (IPTW) analysis to adjust for potential confounders.

Results

Hepatitis B virus infection was the most common cause of HCC. With median follow-up duration of 11.9 for atezolizumab-bevacizumab and 20.9 months for the lenvatinib groups, patients treated with atezolizumab-bevacizumab exhibited superior progression-free survival (PFS) and overall survival (OS) than those treated with lenvatinib (median PFS 6.3 vs. 4.9 months, p = 0.031; and median OS 18.5 vs. 11.3 months, p < 0.001). After IPTW adjustment, atezolizumab-bevacizumab remained associated with favorable OS (median OS of 17.9 vs. 12.3 months, p = 0.010). Treatment with atezolizumab-bevacizumab was an independent factor of OS in both the entire and IPTW-adjusted cohorts. For patients with a viral etiology, the atezolizumab-bevacizumab group exhibited significantly longer OS than the lenvatinib group in both entire and IPTW-adjusted cohorts (p < 0.001 and p = 0.006, respectively). Conversely, both groups showed comparable OS among those with a nonviral etiology (p = 0.656 and p = 0.616, respectively).

Conclusions

Atezolizumab-bevacizumab showed superior OS compared to lenvatinib in Asian patients with unresectable HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesBevacizumabAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultProgression-Free Survival

Stichwörter der Autor:innen

Atezolizumab-bevacizumabHepatocellular carcinomaInverse probability treatment weighting analysisLenvatinibOverall survival

Substanzen

lenvatinibatezolizumabPhenylurea CompoundsQuinolinesBevacizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, dr.choi85@gmail.com.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, yooc@amc.seoul.kr.

Zitieren

APA

Kim, H. D., Park, Y. G., Hong, H., Chung, S. W., Kim, S., Ryu, M. H., Ryoo, B. Y., Choi, J., Lee, D., Shim, J. H., Kim, K. M., Lim, Y. S., Lee, H. C., Choi, W. M., & Yoo, C. (2025). Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma. Oncology, 104(1), 40-50. https://doi.org/10.1159/000545351

Vancouver

Kim HD, Park YG, Hong H, Chung SW, Kim S, Ryu MH, et al. Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma. Oncology. 2025;104(1):40-50. doi:10.1159/000545351

BibTeX
@article{Kim2025,
  author = {Kim, Hyung-Don and Park, Young-Gyu and Hong, Hyeyeon and Chung, Sung Won and Kim, Sejin and Ryu, Min-Hee and Ryoo, Baek-Yeol and Choi, Jonggi and Lee, Danbi and Shim, Ju Hyun and Kim, Kang Mo and Lim, Young-Suk and Lee, Han Chu and Choi, Won-Mook and Yoo, Changhoon},
  title = {Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma},
  journal = {Oncology},
  year = {2025},
  volume = {104},
  number = {1},
  pages = {40--50},
  doi = {10.1159/000545351}
}
Kostenlos starten →